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Dermatofibrosarcoma protuberans (DFSP) is an ag-
gressive spindle cell neoplasm. It is associated with
the chromosomal translocation, t(17:22), which fuses
the COL1A1 and PDGF genes. We determined the
characteristic gene expression profile of DFSP and
characterized DNA copy number changes in DFSP by
array-based comparative genomic hybridization (ar-
ray CGH). Fresh frozen and formalin-fixed, paraffin-
embedded samples of DFSP were analyzed by array
CGH (four cases) and DNA microarray analysis of
global gene expression (nine cases). The nine DFSPs
were readily distinguished from 27 other diverse soft
tissue tumors based on their gene expression pat-
terns. Genes characteristically expressed in the DFSPs
included PDGF and its receptor, PDGFRB, APOD,
MEOX1, PLA2R, and PRKCA. Array CGH of DNA ex-
tracted either from frozen tumor samples or from
paraffin blocks yielded equivalent results. Large areas
of chromosomes 17q and 22q, bounded by COL1A1
and PDGF, respectively, were amplified in DFSP.
Expression of genes in the amplified regions was
significantly elevated. Our data shows that: 1) DFSP
has a distinctive gene expression profile; 2) array
CGH can be applied successfully to frozen or forma-
lin-fixed, paraffin-embedded tumor samples; 3) a
characteristic amplification of sequences from chro-
mosomes 17q and 22q, demarcated by the COL1A1
and PDGF genes, respectively, was associated with
elevated expression of the amplified genes. (Am J
Pathol 2003, 163:2383–2395)
Dermatofibrosarcoma protuberans (DFSP) is an uncom-
mon soft tissue neoplasm of young adults with a propen-
sity for locally aggressive growth. This tumor typically
arises in the subcutaneous tissues of the trunk and prox-
imal extremities and is composed of uniform spindle cells
of uncertain histogenesis. Most DFSPs are cured by wide
surgical excision, but local recurrence occurs in approx-
imately 20% of cases.
1 In some instances, radiotherapy
can be of benefit.
2 Death due to metastatic disease is
very rare (5%),
1 and there have been isolated reports of
apparently successful treatments for metastatic disease
with imatinib.
3,4 Virtually all cases of DFSP have a trans-
location that involves chromosomes 17 and 22, resulting
in fusion of the collagen type I  I( COL1A1) and platelet-
derived growth factor  (PDGF) genes.
5,6 The regula-
tory sequences of COL1A1 lead to increased expression
of a fusion transcript that is processed to wild-type
PDGF, which has transforming activity when expressed
at high levels.
7,8 The translocation is most commonly
located on a ring chromosome with varying amounts of
DNA derived from chromosomes 17 and 22, and some-
times also from other chromosomes,
9 associated with
amplification. To date, the areas of amplification have
only been crudely mapped using conventional genomic
hybridization.
10–12 Fusion of COL1A1 and PDGF is also
encountered in giant cell fibroblastoma, a rare tumor
typically seen in children. Currently these two tumors are
thought to be variants of the same lesion.
5,6
Expression profiling using cDNA microarrays has re-
sulted in molecular subclassification of a wide variety of
tumors, including lymphomas,
13 lung carcinomas,
14 and
breast carcinomas.
15 Gene expression profiling with
cDNA microarrays has also proven useful as an aid in the
differential diagnosis of mesenchymal tumors, where
morphological features show significant overlap.
16–20
cDNA microarrays have been used not only for gene
expression studies but also for high-resolution compara-
tive genomic hybridization (array CGH). By using the
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2383same microarrays for both array CGH and cDNA expres-
sion studies on the same tumor samples, Pollack et al
21
found that changes in gene copy number were consis-
tently associated with corresponding changes in expres-
sion of the affected genes. In the case of breast carci-
noma, the majority of amplified genes showed increased
expression, and alterations of gene copy number ac-
counted for a significant component of the altered gene
expression observed in an individual tumor.
In this study we used DNA microarrays to profile gene
expression in DFSP and identified a large number of
genes with consistently high expression in these tumors.
Several potential differential diagnostic markers were
identified, one of which (APOD) is described in detail in a
separate report (West et al, in preparation). In addition,
we characterized DNA copy number alterations in DFSP
at a high resolution and correlated those changes with
expression levels of affected genes. In the course of this
study we found that array CGH could be used success-
fully to analyze formalin-fixed, paraffin-embedded tissue,
circumventing the need for fresh frozen tissue, and mak-
ing possible array CGH studies on samples from surgical
pathology archives.
Materials and Methods
Case Selection
Nine cases of DFSP were used for this study, obtained
from the Departments of Pathology of Stanford University
Medical Center, Vancouver Hospital and Health Sciences
Centre, University of Washington Medical Center, and
Cleveland Clinic Foundation. Fresh frozen tissue, stored
at 80°C was available in each case. The Institutional
Review Board at Stanford University Medical Center ap-
proved the study. The diagnosis of DFSP was based on
the light microscopic appearance of the tumors, with
confirmatory immunohistochemical staining (CD34) per-
formed in each case. All but one of the DFSPs reacted for
CD34, consistent with known staining patterns. For gene
expression studies, a total of 36 soft tissue tumors (STT)
were studied, including the nine cases of DFSP. Non-
DFSPs studied were leiomyosarcoma (eight cases), ma-
lignant fibrous histiocytoma (six cases), of which two
cases could be subclassified as myxofibrosarcoma, gas-
trointestinal stromal tumor (GIST, five cases), synovial
sarcoma (six cases), nodular fasciitis (one case), and
epithelioid fibrous histiocytoma (one case). One of the
GIST cases (STT1823) was a recurrence from a prior
lesion (STT094). The nine DFSP cases, the two myxofi-
brosarcomas, the nodular fasciitis, the fibrous histiocy-
toma, and the recurrence of the GIST lesion are new to
this report. The other lesions functioned as comparison
for gene expression level determination in DFSP and
were previously published as part of a prior study.
16
Array CGH studies were performed using fresh frozen
tissue on four of the nine DFSP cases, and also using
paraffin embedded tissue for three of the four cases. For
comparison, we performed array CGH on four cases of
solitary fibrous tumor (SFT), a soft tissue tumor known to
have a relatively simple karyotype
22 that rarely harbors
chromosome abnormalities in the 17q or 22q regions.
23
DNA was also isolated from paraffin- embedded material
of six fibrous histiocytoma specimens for aCGH studies.
In each case the diagnosis was made based on conven-
tional light microscopic examination, with appropriate ad-
juvant immunohistochemical studies.
Histology and Immunohistochemistry
All cases were reviewed by two pathologists (B.R. and
M.v.d.R.). For immunohistochemistry, sections were
stained with CD34 (Becton Dickinson, Mountain View,
CA) and APOD (Novocastra, Newcastle-on-Tyne, United
Kingdom) using the Envision detection system (DAKO,
Carpinteria, CA).
cDNA Expression Microarray Analysis
The cDNA microarrays used in this study included about
28,000 unique characterized genes or ESTs represented
by a total of 41,859 unique cDNAs printed on glass slides
by the Stanford Functional Genomics Facility (http://
www.microarray.org/sfgf/jsp/home.jsp). The details of the
construction of these arrays were described previously.
15
Preparation of tumor mRNA, labeling, and hybridization
were performed as described in an earlier publication.
15
Briefly, after confirmation of the presence of viable tumor
by frozen section, tissue was homogenized in Trizol re-
agent (Invitrogen, Carlsbad, CA) and total RNA was pre-
pared; mRNA was then isolated using the FastTrack 2.0
method following the manufacturer’s protocol. Prepara-
tion of Cy-3-dUTP (green fluorescent) labeled cDNA from
2 g of reference mRNA and Cy-5-dUTP (red fluores-
cent) labeled cDNA from 2 g of each tumor specimen
mRNA, microarray hybridization and subsequent analy-
sis was performed as described.
15 The reference mRNA
was isolated from a pool of 11 cell lines.
15 After washing,
the microarrays were scanned on a GenePix 4000 mi-
croarray scanner (Axon Instruments, Foster City, CA)
and, after normalization of fluorescence intensities to
control for experimental variation, fluorescence ratios (tu-
mor/reference) were calculated using GenePix software.
The primary data tables and the image files are freely
available from the Stanford Microarray Database
24
(http://genome-www4.stanford.edu/MicroArray/SMD/).
Data were selected using the following criteria: 1) only
cDNA spots with a ratio of signal over background of at
least 1.5 in either the Cy3 or Cy5 channel were included;
2) genes were included for further analysis only if the
corresponding cDNA spots provided data that passed
criterion 1 on at least 29 of 36 arrays (80% good data); 3)
to focus on genes with high variations in expression in
these tumors, we selected genes whose expression level
differed by at least fourfold in at least two specimens from
that gene’s geometric mean expression level across all
36 specimens. Hierarchical clustering analysis
25 and sig-
nificance analysis of microarrays (SAM)
26 were then per-
formed as described previously.
16
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Of the over 41,000 cDNA sequences represented on the
microarrays used for this study, the chromosomal local-
ization is known for 35,151 distinct mapped cDNAs,
which represent 24,540 different Unigene clusters and
3225 cDNAs not yet represented in Unigene clusters.
Tumor DNA from frozen or formalin-fixed, paraffin-embedded
Figure 1. Hematoxylin and eosin staining of a representative case of DFSP (STT491) (A), and a cellular fibrous histiocytoma (STT169) (D), with confirmatory
immunohistochemical staining for CD34 (B and E), and APOD (C and F). The DFSP is positive for CD34 (B), while the cellular fibrous histiocytoma (E) shows
CD34 positivity in endothelial cells only, but not in tumor cells. IHC for APOD is strongly positive in DFSP (C), while the FH fails to stain with antibodies against
APOD (F) despite relative high levels of APOD mRNA.
Table 1. Clinical Data of All DFSP Cases and of the Four DFSP Mimics
Age Sex Site CD34 APOD
STT154-DFSP 46 F Scapula 
STT491-DFSP 41 F Sacrum 
STT1975-DFSP 60 M Rt shoulder 
STT3053-DFSP 49 M Rt shoulder 
STT3068-DFSP 48 F Central back 
STT3126-DFSP 46 F Lt breast 
STT1984-DFSP 32 F Abd wall 
STT1971-DFSP 37 F Lt ant abd wall 
STT2285-DSFP 37 M Rt thigh 
STT 604-NF 50 F Submandibular 
STT 625-myxofibrosarc 65 F Chest 
STT 640-myxofibrosarc 67 F Rt arm 
STT 169-FH 72 F Rt arm 
F, female; M, male; Rt, right; Lt, left; Abd, abdominal; ant, anterior.
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human leukocytes) were extracted; see protocols on
accompanying website (http://genome-www.stanford.edu/
DFSP/). Frozen tumor DNA and reference DNA were
digested with DpnII before further processing. Gel elec-
trophoresis of digested and non-digested DNA isolated
from formalin-fixed, paraffin-embedded tissue was run to
determine DNA fragment size. Labeling of DNA isolated
from tumor samples, after light-microscopic confirmation
of the presence of non-necrotic tumor, was performed as
described previously
21 (http://cmgm.stanford.edu/
pbrown/protocols/index.html). Briefly, 2 to 4 g of tumor
DNA was fluorescently labeled (Cy5) in a volume of 50
microliters, mixed with reference DNA labeled with Cy3,
and hybridized overnight to the array. After washing, the
array slides were scanned on a GenePix Scanner (Axon
Instruments) and fluorescence ratios (test/control) calcu-
lated using GenePix software. Only cDNA spots with a
ratio of signal over background of at least 1.5 in the Cy3
channel were included in further analysis. Chromosomal
localization of the mapped genes was assigned as de-
scribed previously
21 and is based on Goldenpath data
from June 28, 2002. For CGH data the copy number for
each locus was based on a moving average of the five
nearest cDNA clones centered on that locus.
21 For chro-
mosome 17 and 22, 1224 and 527 genes were selected
respectively, and the same genes were used to display
centered expression levels for four DFSPs and three SFTs
in Figure 4.
Statistical Analysis
For statistical tests the SPSS version 10.0 statistical soft-
ware package (SPSS, Inc., Chicago, IL) was used.
Results
Histology and Immunohistochemistry
The nine cases of DFSP studied here were all typical
DFSP based on their histological features and/or immu-
nohistochemical staining profiles (Figure 1). Clinical and
immunohistochemical features of the DFSPs are shown in
Table 1. The 27 cases of non-DFSP tumors chosen for
comparison by gene expression profiling included four
tumors with histological features similar to those of DFSP.
One, STT169, (Figure 1) was a cellular fibrous histiocy-
toma, the lesion with which DFSP is most often confused.
The distinction between these two neoplasms is critical,
as histiocytomas are almost invariably benign and re-
quire less aggressive treatment. Three other lesions, two
myxofibrosarcomas (STT625, STT640) and one case of
nodular fasciitis (STT604) can be confused histologically
with the myxoid variant of DFSP. The clinical and immu-
nohistochemical features of the four DFSP mimics are
also shown in Table 1. The histology of the nine DFSPs,
and the four lesions in its differential diagnosis can be
found on the supplemental Figure 1 (http://genome-www.
stanford.edu/DFSP/). The histology of the remaining 23 STT
can be found on the supplemental website of an earlier
publication (http://genome-www.stanford.edu/sarcoma/).
Gene Expression Data
This report focuses on variation among these tumors in
expression of 4687 of the 28,597 genes or ESTs repre-
sented on our microarrays. These were genes for which
we consistently were able to obtain technically adequate
measurements and where expression levels varied sub-
stantially among the 36 samples analyzed (Figure 2A).
We first used an unsupervised hierarchical clustering
method to highlight groups of tumors with similarities in
global gene expression patterns. Hierarchical clustering
analysis organizes genes into groups with similar expres-
sion patterns, facilitating recognition of functional themes
in the expression patterns, and similarly organizes the
soft tissue neoplasms into distinct groups. The results are
displayed in Figure 2A in the form of a table in which the
expression pattern of each gene in each tumor is repre-
sented using a color key and dendrograms are used to
represent relationship among the tumors. The nine cases
of DFSP clustered closely together based on their global
gene expression patterns, indicating that they were
closely related to each other and significantly different
from the other tumors profiled (Figure 2B). The 4 cases
representing alternative diagnoses in the differential di-
agnosis of DFSP (STT640, STT625, STT169, STT604)
clustered separately from the cases of DFSP.
DFSP specimens were distinguished from the other
neoplasms by a large cluster of 465 genes whose pat-
terns of variation in expression among these tumors were
highly correlated (correlation coefficient with groupwise
mean pattern of 0.63, see black bar, Figure 2A). Within
this cluster is a subcluster of 98 genes including the
PDGF and PDGFRB genes, shown in Figure 2C. The
complete dataset is available in a searchable format on
the accompanying website (http://genome-www.stan-
ford.edu/DFSP/), where the 465 genes are also listed as
Web Table 2. The DFSPs expressed high levels of PDGF
transcripts, consistent with the known significance for this
Figure 2. Hierarchical cluster analysis of gene expression profiles of 36 tumors, including nine DFSPs. Each row represents the relative level of expression for
a single gene, centered at the geometric mean of its expression level across the 36 samples. Each column shows the expression levels for a single sample. The
red or green colors indicate high or low expression, respectively, relative to the mean. The intensity of the colors indicates the magnitude of deviation from the
mean (see color bar). Gray denotes missing data. A: Overview of expression pattern of the 4687 genes used for hierarchical clustering analysis. The black vertical
bar highlights a cluster of 465 genes that are characteristically expressed in DFSP. The yellow, green, and blue bars indicate the areas shown in more detail in
C, D, and E. B: The same clustering analysis shown in A but with only a subset of the gene expression data displayed, consisting of genes most characteristic of
the DFSPs. At the top is the dendrogram depicting the relatedness between tumor samples, with short branches denoting a high degree of relatedness (see
correlation coefficient bar). DFSP is shown in blue. Leio, leiomyosarcoma; MFH, malignant fibrous histiocytoma; N.Fasciitis, nodular fasciitis; Fibr. Histiocytoma,
cellular fibrous histiocytoma (in green); Synsarc, synovial sarcoma; GIST, gastrointestinal stromal tumor. Gene names are shown on the right. C: Relative mRNA
levels in the 36 tumors for a set of 98 genes (correlation coefficient 0.82) that clustered with the PDGF gene. D: Expression level of CD34, measured by two
separate spots on the arrays. E: Expression level of CD68, measured by three separate spots on the arrays.
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nine DFSPs, STT3053, did not show an elevated level of
PDGF expression. The lack of PDGF mRNA expression
as seen by gene array analysis in this case (using two
separate cDNAs for PDGF mRNA) was confirmed by in
situ hybridization studies (data not shown). Despite the
lack of elevated PDGF expression in case STT3053 this
is still considered a classic example of DFSP, based on
histology and immunohistochemistry. The histology is
available on the accompanying website and the tumor
reacted for CD34 (see Table 1). The expression pattern of
several thousands of genes, shared by case STT3053
and the other DFSP cases further supports this. Impor-
tantly, the receptor for PDGF, PDGFRB, was also highly
expressed in the group of DFSPs. High levels of CD34
transcripts and low expression of CD68 in DFSPs com-
pared to non-DFSPs, are consistent with the known im-
munohistochemical profile of these tumors (Figure 2, D
and E).
27–29 A cellular fibrous histiocytoma (case
STT169) unexpectedly showed moderately high levels of
CD34 mRNA. However, immunohistochemical staining of
this tumor shows that CD34 protein is expressed by
endothelial cells, rather than the tumor cells themselves
(Figure 1E). Although APOD mRNA was highly expressed
in both DFSPs and the cellular fibrous histiocytoma
(STT169), immunohistochemistry for APOD protein
showed expression only in the DFSPs but not in the
histiocytoma (Figure 1F). The full explanation for this dis-
crepancy is unknown. However posttranslational modifi-
cations such as glycosylation may account for this effect.
In addition in several instances, discrepancies between
mRNA levels and protein levels have been described, for
example in bcl2 expression.
30
We used a supervised analytical method, SAM (Signif-
icance Analysis of Microarrays), as an alternative way to
search for differentially expressed genes that distinguish
DFSP from the other sarcomas.
26 A list of the 259 genes
(288 cDNAs) most consistently expressed at higher lev-
els in DFSP, as determined by SAM, is available on the
accompanying website (supplementary Table 2, http://
genome-www.stanford.edu/DFSP/) with their chromo-
somal location. The top 50 genes, most responsible for
the distinction between DFSP and the other soft tissue
lesions, is shown in Table 2. These genes representing
candidate diagnostic markers for DFSP, include APOD,
which stained all nine DFSPs in this study and failed to
react with the single histiocytoma (despite high levels of
mRNA in that lesion). The utility of APOD as an immuno-
histochemical marker is described in detail in a separate
report (West et al, in preparation).
Array Comparative Genomic Hybridization
Array CGH analysis of four DFSP cases revealed abnor-
malities of chromosome arm 17q and 22q in all cases
(Figure 3), corresponding to the most commonly identi-
fied cytogenetic abnormality in DFSP, a ring chromosome
containing portions of chromosomes 17q and 22q, r(17:
22).
23 This ring chromosome results in fusion of the
COL1A1 and PDGF genes. In contrast, 4 cases of sol-
itary fibrous tumors, showed no significant areas of am-
plification or deletion. The areas of amplification of chro-
mosomes 17 and 22 in DFSP start at the PDGF and
collagen 1A1 genes, such that the PDGF and collagen
1A1 constitute one of two borders in a contiguous ampli-
fied segment of 22q, and 17q respectively, (Figure 3,
Panel A, B). One or more additional genetic abnormalities
were identified in every case and gains and losses at
some loci were seen in more than one case (see supple-
mental Figure 3). For instance, we observed recurrent
gains of chromosome 5 (STT1971, STT1984), chromo-
some 7p (STT154, STT1971), chromosome 8 (STT154,
STT1971, STT1984), chromosome 18 (STT1971,
STT1984), and chromosome 21 (STT1971, 1984). In ad-
dition, loss of large parts of chromosome 19 was ob-
served in STT1971 and STT1984. Many of the apparent
losses and gains affected small segments of chromo-
somes and would not be expected to be detectable
cytogenetically or by conventional comparative genomic
hybridization.
Array CGH Analysis of Frozen versus
Formalin-Fixed, Paraffin-Embedded Tissue
To test the feasibility of array CGH analysis of formalin-
fixed, paraffin-embedded tumor samples we analyzed
both fresh frozen and formalin-fixed, paraffin-embedded
material from the same tumor, in three cases of DFSP. In
each case the essential results were very similar (Figure
3). In an attempt to demonstrate the potential clinical
usefulness of aCGH in the differential diagnosis of other
lesions, we performed aCGH on five cases of fibrous
histiocytoma, for which only paraffin material was avail-
able. All cases showed a lack of significant areas of gene
amplification by this technique, including in the areas of
chromosome 17 and 22 affected in DFSP (Figure 5 and
accompanying website).
Correlation of Array CGH and Gene
Expression Data
Comparison of array CGH and gene expression data
could be done in four cases of DFSP. For these cases the
copy number and gene expression were compared for
the 27,765 genes for which the chromosomal location has
been mapped. A correlation was observed between in-
creased gene copy number and increased gene expres-
sion. This influence of DNA copy number on gene ex-
pression is evident in the colored map representations of
DNA copy number and mRNA levels for 1224 genes on
chromosome 17 and 527 genes on chromosome 22 (Fig-
ure 4). From visually inspecting Figure 4 it appears that
there is a considerable difference in levels of expres-
sion between the regions of chromosomes 17 and 22,
bounded by the COL1A1 and PDGF genes, respec-
tively. To test this observation more formally, using the
difference in average mRNA levels between the DFSP
and SFT specimens, we considered a change-point mod-
2388 Linn et al
AJP December 2003, Vol. 163, No. 6el
31 with a single change in average expression level
occurring on chromosome 17 and another change on
chromosome 22. The maximum likelihood estimate for the
change-point on chromosome 17, based solely on gene
expression measurements, was the gene PHB (prohibitin
Hs.75323, AA055656, chromosome 17, start 47192492),
12 mapped genes toward the p terminus from COL1A1
(Hs.172928, R48843, chromosome 17, start 47864928).
On chromosome 22, the maximum likelihood estimate of
the change-point was MGAT3 (mannosyl (-1,4-)-
glycoprotein -1,4-N-acetylglucosaminyltransferase
Hs.348978, AA421473, chromosome 22, start 36501033),
five mapped genes toward the q terminus from PDGF
(Hs.1976, W72000, chromosome 22, start 36234216). A
95% confidence region for the location of the change-
point on chromosome 17 barely excluded the COL1A1
gene; a 95% confidence region for the location of the
change-point on chromosome 22 included the PDGF
gene. Despite the significant correlation between ampli-
fication levels and expression levels it is clear that there
remain many examples of amplified genes that are not
overexpressed.
Table 2. First 50 Genes with Highest Differential Expression in DFSP According to SAM Analysis
Gene
symbol Gene name UniGene # GenBank #
SAM
score(d)
ESTs Hs.32345 AI668612 11.1886
EGR2 Early growth response 2 Hs.1395 AA446027 9.893322
PLA2R1 Phospholipase A2 receptor 1, 180 kD Hs.171945 W04525 9.403624
PCDH18 Protocadherin 18 Hs.97266 AA704401 9.161416
ESTs ESTs Hs.192262 AI192496 8.982065
LOC51136 LOC51136 PTD016 protein Hs.30154 N51514 8.894226
LFNG Lunatic fringe homolog Hs.159142 R56561 8.826694
OMD Osteomodulin Hs.94070 N32201 8.450854
CHRFAM7A CHRNA7 and FAM7A fusion Hs.353211 W93369 8.396351
PDGF Platelet-derived growth factor  polypeptide Hs.1976 W72000 8.303292
ESTs Hs.348762 AA700772 8.011256
ESTs Hs.323780 N22836 7.949673
KIAA1211 KIAA1211 protein Hs.205293 N35889 7.908669
Homo sapiens cDNA FLJ12815 fis, clone NT2RP2002546 Hs.49476 AA284237 7.765829
ARVCF Armadillo repeat gene deletes in velocardiofacial syndrome Hs.171900 H17198 7.637739
CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast) Hs.75929 AA136983 7.589666
CEP4 Cdc42 effector protein 4; binder of Rho GTPases 4 Hs.3903 AA449061 7.490882
MEOX1 Mesenchyme homeo box 1 Hs.438 AA426311 7.461304
APOD Apolipoprotein D Hs.75736 H15842 7.457497
PLG Plasminogen Hs.75576 T73090 7.127251
FZD7 Frizzled homolog 7 Hs.173859 N69049 7.07609
Homo sapiens, clone IMAGE:3450973, mRNA Hs.7921 AA620437 7.042933
SPRY2 Sprouty homolog 2 Hs.18676 AA453759 7.038161
ESTs Hs.355694 AA778653 6.995952
ESTs Hs.164680 AA463229 6.980936
POPX1 Partner of PIX 1 Hs.166351 W40125 6.959919
MS12 Musashi homolog 2 Hs.173179 N45139 6.9322
ABCA9 ATP-binding cassette, sub-family A (ABC1), member 9 Hs.301496 AI822061 6.920054
ESTs Hs.268874 R98003 6.890625
ELLS1 Hypothetical protein Ells1 Hs.7913 N29882 6.860183
KIAA0638 KIAA0638 protein Hs.77864 AA405486 6.84359
ABCA6 ATP-binding cassette, sub-family A (ABC1), member 6 Hs.15780 AA099357 6.838837
SEPT6 Septin 6 Hs.90998 AA868745 6.75616
ESTs Hs.50162 N67355 6.715135
SPAG9 Sperm-associated antigen 9 Hs.129872 AA399253 6.580305
KIAA0937 KIAA0937 protein Hs.62264 AA487527 6.579918
Homo sapiens clone 24628 mRNA sequence Hs.129997 AA885845 6.569535
KLF5 Kruppel-like factor 5 (intestinal) Hs.84728 R27011 6.539115
IL11RA Interleukin 11 receptor,  Hs.64310 AI822086 6.526972
FLJ90754 Homo sapiens mRNA full-length insert cDNA clone Hs.8963 AA424560 6.520919
ACVRL1 Activin A receptor type II-like 1 Hs.172670 H42572 6.520158
PTGFRN Prostaglandin F2 receptor negative regulator Hs.300591 T83630 6.477428
ESTs Hs.247150 AA459734 6.474894
DHRS6 Oxidoreductase UCPA Hs.124696 R97516 6.466339
TTYH2 Tweety homolog 2 Hs.27935 AA434395 6.45494
SCDGF-B Spinal cord-derived growth factor-B Hs.112885 AA904948 6.433207
DACT1 Heptacellular carcinoma novel gene-3 protein Hs.48950 AA487274 6.426798
GPM6B Glycoprotein M6B Hs.5422 N59368 6.411646
LZTS1 Leucine zipper, putative tumor suppressor 1 Hs.93605 H09757 6.3579
NRXN3 Neurexin 3 Hs.247837 AA450335 6.285427
Input parameters for SAM analysis: imputation engine is “10-nearest neighbor imputer”; data type is “two class, unpaired data”; data are in log
scale; number of permutations is 1000; No blocked permutations; RNG seed is 1234567; (delta, fold change) is (2.46002); (upper cutoff, lower cutoff)
is (4.02194, 6.08331). Computed quantities are: computed exchangeability factor S0 is 236.1422; S0 percentile is 0; false significant number
(median, 90%) is (0.57990, 0.57990); false discovery rate (median, 90%) is (0.19928, 0.19928); Pi0Hat is 0.5799.
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consistently associated with a diagnosis of DFSP, 12%
(31 genes) were localized to the regions of recurrent
amplification on chromosomes 17 (23 genes) and 22 (8
genes), as determined by array CGH (Table 3), although
the amplified segments of chromosomes 17 and 22 con-
tain only 3% of all mapped genes (P  0.001, Binomial
test-exact). Although genes in regions of amplification
tended to be more highly expressed, many of the genes
that distinguish DFSP from other tumors are in regions
without apparent changes in DNA copy number.
The full data sets for the array CGH and gene expres-
sion microarray studies can be accessed through the
Stanford Microarray Database website and through
http://genome-www.stanford.edu/DFSP/.
Discussion
Dermatofibrosarcoma protuberans was first described in
1924, but the cell of origin for this lesion remains un-
known, and cases of DFSP continue to pose difficulties in
differential diagnosis.
32 The uncertainties result from the
tumor’s histology, consisting of bland spindle cells that
lack distinctive growth or cytological features, and the
lack of specific immunohistochemical markers for this
tumor. The correct diagnosis is critical, as DFSPs are
locally aggressive tumors that need a wide surgical ex-
cision, whereas other lesions in the differential diagnosis
of DFSP, such as fibrous histiocytoma, can be treated
less aggressively. The local relapse rate of DFSP is
around 20%. Relapses are often due to incomplete sur-
gical resection.
1
Gene expression profiling has been applied to a wide
range of tumors and has repeatedly been successful in
recapitulating established histological classifica-
tions,
13–16 and in identifying clinically relevant new sub-
types of tumors, when routine diagnostic approaches
have failed to do so.
13–15,33–38
In the case of mesenchymal tumors, we have previ-
ously shown that some types of sarcomas, such as sy-
novial sarcomas, neural tumors, and gastrointestinal stro-
mal tumors, are very homogenous, based on their gene
expression profile. In contrast, others, such as liposarco-
mas, leiomyosarcomas, or malignant fibrous histiocyto-
mas, show considerable heterogeneity and often over-
lapping molecular features.
16
The nine cases of DFSP in this study clustered closely
together relative to a diverse set of non-DFSP sarcomas
based on their gene expression patterns. These tumors
were clearly separable from histologically similar STT by
the expression of a distinct set of genes, including
PDGF, one of the fusion partners of the COL1A1:PDGF
Figure 3. Pairwise comparison of array CGH on three cases of DFSP with DNA isolated from fresh frozen tumor and from formalin-fixed, paraffin-embedded
tumor showing nearly identical regions of amplification on chromosomes 17 and 22. In contrast, five cases of solitary fibrous tumor show no significant changes
on these chromosomes. Genes are arranged in order along the chromosome. Red indicates gene amplification, green indicates gene deletion. A: Magnified view
of start of amplification region on chromosome 17. Note that this area starts at the location of COL1A1, one of the fusion partners in the t(17:22). B: Magnified
view of start of amplification region on chromosome 22, starting at the location of PDGF, the other fusion partner in the t(17:22).
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role that the fusion product is thought to play in the
tumorigenesis of DFSP. In addition, PDGFBR, the recep-
tor for PDGF, was highly expressed in DFSP, suggest-
ing that an autocrine stimulatory loop may contribute to
the tumorigenesis. In a previous study we had made a
similar observation for synovial sarcoma, where SSX, one
of the fusion partners of the t(X;18) SYT:SSX transloca-
tion, was present in the cluster of relatively highly ex-
pressed genes that distinguished synovial sarcoma from
the other STT.
16
To investigate the potential utility of gene expression
profiles in the differential diagnosis of DFSP, we also
analyzed in this study four tumors that can be misdiag-
nosed as DFSP. The DNA microarray analysis clearly
showed that these tumors were molecularly distinct
from DFSP.
cDNA microarray analysis provides an efficient way to
search for new diagnostic markers for routine immuno-
histochemistry. CD34 is a commonly used marker in the
diagnosis of DFSP but, like many single markers, it is
neither completely sensitive nor specific.
39 The charac-
teristic gene expression pattern of DFSP included several
new candidate diagnostic markers, including APOD,
EGR2, PLA2R1, and MEOX1. Antibodies against APOD
stained tumor cells of all DFSPs in this study, but did not
stain the fibrous histiocytoma, despite the high levels of
APOD mRNA detected in this tumor. A more detailed
description of the reactivity of the APOD antibodies will
be described elsewhere (West et al, manuscript in prep-
aration).
Several genes that are normally expressed during
early embryogenesis and involved in somitogenesis, in-
cluding MEOX1, HEY1, and HEYL,
40–44 were character-
istically expressed in DFSP. During murine embryogene-
sis, MEOX1 is expressed in the dermomyotome
40–42 and
in sclerotomally derived cells and muscle cells that form
the body wall,
41 perhaps paralleling the predominant
localization of DFSPs in the dermis of the trunk, and
suggesting the possibility that DFSPs originate from
these early embryonic mesenchymal cells. In a genome-
wide gene expression study of normal human vascula-
ture, HEY1 and HEYL were found to be relatively highly
expressed in the microvascular endothelial cells of skin,
dermis, lung, and intestine (Jen-Tsan Chi, manuscript in
preparation). Preliminary studies have shown that anti-
bodies against HEY1 react with DFSP tumor cells (data
not shown).
DFSPs have already been characterized by several
cytogenetic studies.
23 The presence of a ring chromo-
some has been the most consistent genetic abnormality
identified in DFSP, being present in more than 75% of
cases, sometimes as the only detectable cytogenetic
abnormality.
23,45,46 By conventional cytogenetics and
comparative genomic hybridization, the ring chromo-
some was shown to be composed of sequences from
Figure 4. Comparison of aCGH data of chromo-
somes 17 and 22 in four DFSP with mRNA levels of
same genes relative to aCGH data and expression
levels in SFT.
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12,47 leading to the recognition
that the fusion of COL1A1 and PDGF in DFSP is related
to formation of the ring chromosome, or in occasional
cases leads to a t(17:22) translocation.
5 Deregulated ex-
pression of wild-type PDGF protein has transforming
activity in NIH3T3 cells
7,8 and is thought to play a critical
role in the genesis of DFSP, but it is not clear whether
other genetic abnormalities are also required for tumor
development. Nishio et al
10 have performed conventional
comparative genomic hybridization on 12 cases of DFSP,
finding 0 to 3 genetic abnormalities per tumor (mean 1.9).
Besides changes in chromosomes 17 and 22, they found
gains of copy number of chromosome 8q24.1-qter in
three tumors. They did not identify any instances of loss
of DNA sequences. By array CGH analysis, we found that
abnormalities of chromosomes 17 and 22, consisting of
an amplification of large regions of chromosome 17 and
22 bounded by the genes involved in t(17;22), COL1A1,
and PDGF, were present in all four cases we studied.
This suggests that these abnormalities may have a role in
tumorigenesis, in concert with deregulated expression of
PDGF.
Previous studies have shown that paraffin-embedded
tissue can be used for array CGH analysis using 2400
element BAC arrays.
48 We found that formalin-fixed, par-
affin-embedded material is also suitable for array CGH
using higher resolution genome-wide cDNA arrays, ex-
panding the potential application of array CGH to large-
scale retrospective studies of cancer. The average res-
olution of aCGH can be estimated by dividing the haploid
genome size (1.5 billion bp) by the number of mapped
genes on the array (26,000), which equals 60 kb. This
is a conservative estimate of resolution, because genes
are generally more closely spaced in the gene-rich por-
tions of chromosomes. By using this conservative esti-
mate, array CGH has a resolution 150 times that of
conventional CGH, which is estimated at 10–20 MB for
deletions.
49 The aCGH technique can thus be used to
distinguish DFSP from lesions in its differential diagnosis,
Figure 5. Array-based DNA copy number profiles of DFSP STT154 (A) and fibrous histiocytoma 089 (B). Individual cDNAs are arranged according to their known
location along human chromosomes, to produce a representation of tumor DNA copy number changes mapped onto the normal human genome. Each vertical
line (red or green) indicates the position of a single cDNA clone, and the length of the line corresponds to the log10 fluorescence ratio of tumor versus reference
DNA for that locus, reported as a moving average of five adjacent clones. Red lines indicate areas of amplification and green lines indicate areas of deletion.
A: The DFSP shows characteristic increase in material on chromosomes 17 and 22. B: The fibrous histiocytoma shows absence of significant amplification of
chromosomes 17 and 22. Raw data from all paraffin DNA aCGH experiments can be downloaded from SMD, and figures of all aCGH experiments and histology
in this paper can be seen at http://genome-www.stanford.edu/DFSP/.
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as is shown here for five cases of fibrous histiocytoma.
The use of the same cDNA microarrays for array CGH
and gene expression profiling allows correlation of
changes of gene copy number with gene expression on
a genome wide scale. Pollack et al
21 were able to show a
strong correlation between copy number changes and
gene expression, and concluded that at least 12% of
variation in gene expression among the breast carcino-
mas examined was directly attributable to changes in
gene copy number. Unlike breast carcinomas, DFSPs
show one consistent genetic abnormality (COL1A1-
PDGF fusion) with relatively few other genetic alter-
ations. Examination of gene expression in DFSP identified
elevated expression of PDGF as a consistent feature.
Array CGH showed amplification of the PDGF gene. In
addition, 31 of the 259 genes that we found by SAM
analysis to be consistently more highly expressed in
DFSP than in other STT were located in the amplified
regions of chromosomes 17 and 22. This highlights the
potential role of other genes in the amplified regions of
chromosomes 17 and 22 in DFSP tumorigenesis, as sug-
gested previously by others.
11 Several of these 31 genes
appear particularly worthy of further attention. TBX2 (Ta-
ble 3), a gene in the amplified region of chromosome 17,
encodes a transcription factor that can immortalize cell
by down-regulating CDKN2a (p14
ARF) and that has been
found to be expressed at an elevated level in a subset of
human breast carcinomas.
50 TBX2 is highly expressed in
DFSP. Protein kinase C  is encoded by another of the 31
genes that are both amplified and highly expressed in
DFSP. PRKA has roles in regulation of cell growth, differ-
entiation, and transformation.
51,52 Although a generic
protein kinase C inhibitor (calphostin C) does not inhibit
DFSP cell growth in vitro,
53 an anti-sense oligonucleotide
that specifically inhibits expression of PRKA has been
shown to be active in several phase I studies in patients
with a variety of malignancies.
54,55 GRB2, amplified on
chromosome 17 (Table 2) and highly expressed in DFSP,
belongs to the group of proteins with SH2 and SH3 do-
mains that link tyrosine kinases to intracellular path-
ways.
56 For instance, after activation of a PDGFRB re-
ceptor, GRB2 binds as an adaptor molecule to the
receptor and then complexes with SOS1, which leads to
RAS activation (see web figure 4).
57 In a mouse model
that used the polyomavirus middle T antigen to induce
mammary carcinomas, the onset of mammary tumorigen-
esis was significantly delayed in mice heterozygous for
an inactivating Grb2 mutation.
58 The hypothesis that high
GRB2 expression in DFSP contributes to tumorigenesis in
DFSP may warrant further investigation. PRKA and GRB2
both act downstream of the PDGF receptor (web figure 4).
A single case of DFSP (STT3053) was noted to lack
PDGF overexpression. This finding raises the question
whether another signaling gene mutation that might sub-
stitute for PDGF could be present in this case. A similar
situation has been described in gastrointestinal stromal
tumors where it was recently reported that PDGFRA ac-
tivation mutations could substitute for the usual KIT mu-
tations found in these tumors.
58
Table 3. 31 Genes Amplified on chr17 or 22 and Differentially and Highly Expressed in DFSP
Gene symbol Gene name Region of amplification
MEOX1 Mesenchyme homeobox 1 17q21
SPAG9 Sperm-associated antigen 9 17q21
ESTs N26608 17q23
ESTs AI339225 17q23
MS12 Musashi homolog 2 17q24
POPX1 Partner of PIX1 17q24
ESTs AA046023 17q24
ESTs N51514 LOC51136 PTD016 protein 17q24
TBX2 T-box 2 17q24
ESTs AI203113 17q24
AXIN2 Axin 2 (conductin, axil) 17q24
PRKCA Protein kinase C,  17q25
ESTs R98003 17q25
ABCA9 ATP-binding cassette, sub-family A (ABC1), member 9 17q25
ABCA6 ATP-binding cassette, sub-family A (ABC1), member 6 17q25
CEP4 Cdc42 effector protein 4; binder of Rho GTPases 17q25
TTYH2 Tweety homolog 2 17q25
FDXR Ferredoxin reductase 17q25
ESTs AA452113 17q25
FLJ20753 Hypothetical protein FLJ20753 17q25
RAB40B RAB40B, member RAS oncogene family 17q25
GRB2 Growth factor receptor-bound protein 2 17q25
ESTs AI192496 17q25
PNUTL1 Peanut-like 1 22q11
ARVCF Armadillo repeat gene deletes in velocardiofacial syndrome 22q11
ESTs AA443624 22q11
ESTs H87363 22q11
BK65A6.2 Sushi domain (SCR repeat) containing 22q11
RBM9 RNA binding motif protein 9 22q12
ESTs AI003064 22q12
PDGF Platelet-derived growth factor  polypeptide 22q13
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AJP December 2003, Vol. 163, No. 6In summary, DNA microarray analysis of global gene
expression patterns and gene copy number changes in
DFSP has provided new molecular criteria for the diag-
nosis of this malignancy, suggested potential clues to its
pathogenesis, and identified new candidate molecular
targets for therapy.
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